JAK2 MUTATION (V617F)- PLASMA BASED ANALYSIS

Index:

Order Name JAK 2 PLAS
Test Number: 5572275
Revision Date 09/08/2009

SPECIMEN REQUIREMENTS
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	5 mL (2)	Plasma	EDTA (Lavender Top)	Frozen
Instructions	Collect two 5mL EDTA lavender top tubes, centrifuge and aliquot plasma into plastic pour off tube and freeze with in 2hrs of collection. Frozen plasma is stable for 2 years. Whole Blood Specimens are acceptable at Room temperature and refrigerated temperatures, but are only stable for 72hrs. RML can process the whole blood samples into frozen plasma aliquots as needed provided the sample meets whole blood stability requirements. Whole blood stability: Room temperature= 72hrs. Refrigerated= 72hrs. NOTE: Information regarding draw time and date is required on the sample to ensure the stability of the sample can be maintained.Do Not Freeze Whole Blood Specimens.

GENERAL INFORMATION
Testing Schedule	Monday
Expected TAT	8-16 Days
Clinical Use	Myeloproliferative disorders (MPDs) are clonal hematopoietic stem cell malignancies characterized by excessive production of blood cells by hematopoietic precursors. In addition to thrombotic and hemorrhagic complications, leukemic transformation can occur. The main members of MPD are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Idiopathic Myelofibrosis (MF). The molecular pathogenesis of most MPDs is unknown, This V617F mutation leads to constituitive tyrosine phosphorylation activity that promotes cytokine activity and induces erythrocytosis. The V617F mutation in JAK2 is a dominant gain-of function mutation that contributes to the expansion of the myeolproliferative disorder clone.
Notes	Due to a better resolution and detection of (V617F) mutation on plasma, the Plasma based analysis is the preferred testing method.
CPT Code(s)	83891; 83902; 83898 (x3); 83904; 83912
Lab Section	Reference Lab